BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33171359)

  • 1. Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer.
    Parody-Rúa E; Guevara-Cuellar CA
    Value Health Reg Issues; 2020 Dec; 23():93-98. PubMed ID: 33171359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
    Li X; Li W; Hou L
    Value Health Reg Issues; 2019 May; 18():1-7. PubMed ID: 30412913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
    Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
    Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
    Goulart B; Ramsey S
    Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
    Zheng H; Xie L; Zhan M; Wen F; Xu T; Li Q
    Clin Transl Oncol; 2018 Mar; 20(3):286-293. PubMed ID: 28785913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Ackroyd SA; Huang ES; Kurnit KC; Lee NK
    Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
    Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
    [No Abstract]   [Full Text] [Related]  

  • 13. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.
    Chouaïd C; Crequit P; Borget I; Vergnenegre A
    Clinicoecon Outcomes Res; 2015; 7():9-15. PubMed ID: 25548525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
    BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
    Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
    Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
    Mehta DA; Hay JW
    Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
    Permsuwan U; Thongprasert S; Sirichanchuen B
    Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.